Industry Analysis
Over the last few years, various monoclonal antibodies targeting immunological checkpoints such as CTLA-4, PD-1, and PD-L1 have been approved, each with its own mode of action. Manufacturers are concentrating their efforts on creating medications from many classifications to treat various disorders, from cancer to rare diseases.
Monoclonal antibodies combined...
English
Arabic
Français
Español
Português
Deutsch
Türkçe
Dutch
Russian
Romaian